Major Stroke Prevention: A New Use for a Well-Known Medication

Major Stroke Prevention: A New Use for a Well-Known Medication Posted By:
...

Strokes can have a devastating impact on the long-term survival and function of our patients. Therapies to treat them have been well established, and there has been a reduction in morbidity and mortality as a result. A recent study examined the impact of daily aspirin along with ticagrelor versus aspirin alone on preventing the escalation of transient ischemic attacks (TIA) and stroke into major cardiovascular accidents.

The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) study examined the use of an initial dose of ticagrelor 180 mg followed by 90 mg twice daily for days 2 to 30, compared with placebo, in conjunction with a loading dose of 300 mg to 325 mg of aspirin daily, followed by 75 mg to 100 mg for days 2 to 30. The main measure was time to occurrence for a disabling stroke or death, measured out to 30 days.

The results of this study revealed that the combination of ticagrelor and aspirin was superior in reducing the number of strokes following an initial TIA or stroke compared with aspirin alone.

Some patients within your practice who have other coronary artery diseases may already be taking ticagrelor. Practitioners may consider using ticagrelor plus aspirin to prevent strokes in vulnerable patients. The reduction of stroke incidence and disability can positively impact whether a patient must dramatically change their daily lives, living situation, and support structure—also creating a significant financial impact. To optimize the quality of life and health of patients with previous TIA and stroke, PAs and NPs would benefit from familiarizing themselves with ticagrelor and the THALES study.

References
  • Amarenco P, et al. Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke. JAMA Neurol. 2021;78:177-185.

Share

Filed under: Cardiometabolic

Related
Atrial Fibrillation: Optimizing Outcomes by Addressing Social Determinants of Health and Implicit Bias

Atrial Fibrillation: Optimizing Outcomes by Addres ...

Atrial fibrillation (AF) is the most common sustained arrhythmia diagnosed, and its prevalence is ex ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
My Experience With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes

My Experience With GLP-1 Receptor Agonists in Pati ...

When considering the benefits of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) for our pat ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Dietary Sodium Restriction in Patients With Heart Failure

Dietary Sodium Restriction in Patients With Heart ...

There are about 6.2 million adults in the United States living with heart failure (HF), according to ...

Filed under: Cardiometabolic, Pulmonary Medicine


Continue Reading
Bleeding Risk with Apixaban and Systemic Fluconazole Use

Bleeding Risk with Apixaban and Systemic Fluconazo ...

We, as healthcare professionals, are aware that we must check for drug interactions in our patients ...

Filed under: Cardiometabolic, Pulmonary Medicine


Continue Reading
Cardiovascular Risk in Rheumatic Inflammatory Disease

Cardiovascular Risk in Rheumatic Inflammatory Dise ...

It is well documented that those with rheumatic inflammatory diseases have an increased risk of card ...

Filed under: Cardiometabolic, Rheumatology


Continue Reading
The Latest on Heart Failure: Clinical Trials Summary

The Latest on Heart Failure: Clinical Trials Summa ...

Too often, we are faced with hectic workdays that lead into hectic home lives—when we clock ou ...

Filed under: Cardiometabolic


Continue Reading